These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 23207876

  • 21. Combined use of enalapril and losartan to reduce proteinuria: a question of safety.
    Ellis D.
    Am J Kidney Dis; 2002 Jan; 39(1):209-11. PubMed ID: 11774126
    [No Abstract] [Full Text] [Related]

  • 22. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders.
    Ellis D, Moritz ML, Vats A, Janosky JE.
    Am J Hypertens; 2004 Oct; 17(10):928-35. PubMed ID: 15485756
    [Abstract] [Full Text] [Related]

  • 23. Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis.
    Tylicki L, Renke M, Rutkowski P, Rutkowski B, Lysiak-Szydłowska W.
    Med Sci Monit; 2005 Apr; 11(4):PI31-7. PubMed ID: 15795705
    [Abstract] [Full Text] [Related]

  • 24. Angiotensin blockade as sole treatment for proteinuric kidney disease in children.
    Chandar J, Abitbol C, Montané B, Zilleruelo G.
    Nephrol Dial Transplant; 2007 May; 22(5):1332-7. PubMed ID: 17299000
    [Abstract] [Full Text] [Related]

  • 25. Enalapril: antiproteinuric effect in children with nephrotic syndrome.
    Lama G, Luongo I, Piscitelli A, Salsano ME.
    Clin Nephrol; 2000 Jun; 53(6):432-6. PubMed ID: 10879662
    [Abstract] [Full Text] [Related]

  • 26. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.
    Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM, Cerda J, Carter B, Jung B, Hernandez G, Gipson D, Wyatt RJ.
    Am J Kidney Dis; 2015 Nov; 66(5):783-91. PubMed ID: 26209543
    [Abstract] [Full Text] [Related]

  • 27. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
    Seeman T, Pohl M, Misselwitz J, John U.
    Kidney Blood Press Res; 2009 Nov; 32(6):440-4. PubMed ID: 20016211
    [Abstract] [Full Text] [Related]

  • 28. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ, Stapff M, Lin Y.
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [Abstract] [Full Text] [Related]

  • 29. Enalapril in children with Alport syndrome.
    Proesmans W, Van Dyck M.
    Pediatr Nephrol; 2004 Mar; 19(3):271-5. PubMed ID: 14745635
    [Abstract] [Full Text] [Related]

  • 30. Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients.
    Hoque R, Rahman MS, Iqbal M.
    Bangladesh Med Res Counc Bull; 2009 Aug; 35(2):44-8. PubMed ID: 20120778
    [Abstract] [Full Text] [Related]

  • 31. Long-term therapy with enalapril in patients with nephrotic-range proteinuria.
    Proesmans W, Wambeke IV, Dyck MV.
    Pediatr Nephrol; 1996 Oct; 10(5):587-9. PubMed ID: 8897561
    [Abstract] [Full Text] [Related]

  • 32. Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes.
    Cetinkaya R, Odabas AR, Selcuk Y.
    Int J Clin Pract; 2004 May; 58(5):432-5. PubMed ID: 15206496
    [Abstract] [Full Text] [Related]

  • 33. Antiproteinuric effects of enalapril and losartan: a pilot study.
    White CT, Macpherson CF, Hurley RM, Matsell DG.
    Pediatr Nephrol; 2003 Oct; 18(10):1038-43. PubMed ID: 12920631
    [Abstract] [Full Text] [Related]

  • 34. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators.
    Lang RM, Elkayam U, Yellen LG, Krauss D, McKelvie RS, Vaughan DE, Ney DE, Makris L, Chang PI.
    J Am Coll Cardiol; 1997 Oct; 30(4):983-91. PubMed ID: 9316528
    [Abstract] [Full Text] [Related]

  • 35. Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.
    Shahinfar S, Dickson TZ, Ahmed T, Zhang Z, Ramjit D, Smith RD, Brenner BM, RENAAL Investigators.
    Kidney Int Suppl; 2002 Dec; (82):S64-7. PubMed ID: 12410858
    [Abstract] [Full Text] [Related]

  • 36. Effect of enalapril on glomerular filtration rate and proteinuria in children with chronic kidney disease: a randomized controlled trial.
    Hari P, Sahu J, Sinha A, Pandey RM, Bal CS, Bagga A.
    Indian Pediatr; 2013 Oct; 50(10):923-8. PubMed ID: 23585423
    [Abstract] [Full Text] [Related]

  • 37. ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial.
    Titan SM, M Vieira J, Dominguez WV, Barros RT, Zatz R.
    Clin Nephrol; 2011 Oct; 76(4):273-83. PubMed ID: 21955862
    [Abstract] [Full Text] [Related]

  • 38. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.
    Nakhoul F, Ramadan R, Khankin E, Yaccob A, Kositch Z, Lewin M, Assady S, Abassi Z.
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F880-90. PubMed ID: 15942045
    [Abstract] [Full Text] [Related]

  • 39. Enalapril and prednisone in children with nephrotic-range proteinuria.
    Delucchi A, Cano F, Rodriguez E, Wolff E, Gonzalez X, Cumsille MA.
    Pediatr Nephrol; 2000 Oct; 14(12):1088-91. PubMed ID: 11045392
    [Abstract] [Full Text] [Related]

  • 40. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria.
    Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE.
    J Pediatr; 2003 Jul; 143(1):89-97. PubMed ID: 12915830
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.